By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall ...
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the ...
Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback